BMI falls short as a way to measure obesity. Doctors need to also determine whether body fat harms a person's health.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Proponents of Ozempic microdosing claim you'll reap the drug's benefits with fewer side effects. But is taking small doses of GLP-1 agonists safe and effective for weight loss?

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Drugs like Ozempic and Wegovy are now costing Connecticut taxpayers about $60 million this year and that figure could rise ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate the obesity market, surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData ...

Moreover, Novo Nordisk is now the most valuable company ... to treat diabetes, while Wegovy is primarily prescribed for obesity care. In the same vein, Lilly's Mounjaro is approved by the FDA ...

In terms of its financial performance, Novo Nordisk's bread and butter are its therapies for type 2 diabetes (Ozempic) and obesity (Wegovy); both are the same molecule, semaglutide, which works by ...